{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:59:08Z","timestamp":1788188348271,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatric.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cger.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T11:31:01Z","timestamp":1567769461000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Karlo J.","family":"Lizarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio P.","family":"Strafella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2019.09.004_bib1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: a special essay on the 200th anniversary of the shaking palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson\u2019s disease: the quintessential neuropsychiatric disorder","volume":"26","author":"Weintraub","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson\u2019s disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.cger.2019.09.004_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","article-title":"The relationship of Parkinson disease with aging","volume":"64","author":"Levy","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments of nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson\u2019s disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"Fenelon","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fpsyg.2015.00814","article-title":"Musical hallucinations: review of treatment effects","volume":"6","author":"Coebergh","year":"2015","journal-title":"Front Psychol"},{"key":"10.1016\/j.cger.2019.09.004_bib10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/mds.23835","article-title":"Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years","volume":"26","author":"Goetz","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","article-title":"Hallucinations, REM sleep, and Parkinson\u2019s disease: a medical hypothesis","volume":"55","author":"Arnulf","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11920-009-0029-6","article-title":"The delusional misidentification syndromes: strange, fascinating, and instructive","volume":"11","author":"Christodoulou","year":"2009","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.cger.2019.09.004_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/jnnp.2008.153163","article-title":"Impact of standard of care for psychosis in Parkinson disease","volume":"79","author":"Thomsen","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cger.2019.09.004_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2019.09.004_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2019.09.004_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomized, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cger.2019.09.004_bib18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(10)61855-7","article-title":"Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicenter, double-blind, placebo-controlled randomized trial","volume":"376","author":"van Eijk","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2019.09.004_bib19","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1007\/s12035-015-9350-8","article-title":"Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials","volume":"53","author":"Chen","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.cger.2019.09.004_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib21","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A\u00a012-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2007.05.009","article-title":"A\u00a0profile of neuropsychiatric problems and their relationship to quality of life for Parkinson\u2019s disease patients without dementia","volume":"14","author":"McKinlay","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","article-title":"What predicts mortality in Parkinson disease? A prospective population-based long-term study","volume":"75","author":"Forsaa","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":"Longitudinal outcome of Parkinson\u2019s disease patients with psychosis","volume":"60","author":"Factor","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","article-title":"Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease","volume":"20","author":"Pacchetti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A\u00a0five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2019.09.004_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease","volume":"66","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","article-title":"Intravenous levodopa in hallucinating Parkinson\u2019s disease patients: high-dose challenge does not precipitate hallucinations","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology"},{"issue":"21 suppl 4","key":"10.1016\/j.cger.2019.09.004_bib31","first-page":"S1","article-title":"The scientific and clinical basis of the treatment of Parkinson disease","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","article-title":"Parkinson\u2019s disease, visual hallucinations and apomorphine: a review of the available evidence","volume":"27","author":"Borgemeester","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 2","key":"10.1016\/j.cger.2019.09.004_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/124.2.331","article-title":"Intravenous apomorphine therapy in Parkinson\u2019s disease: clinical and pharmacokinetic observations","volume":"124","author":"Manson","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.cger.2019.09.004_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cger.2019.09.004_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2019.09.004_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.pra.0000450319.21859.6d","article-title":"QTc prolongation with antipsychotics: is routine ECG monitoring recommended?","volume":"20","author":"Shah","year":"2014","journal-title":"J\u00a0Psychiatr Pract"},{"key":"10.1016\/j.cger.2019.09.004_bib37","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2019.09.004_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","article-title":"Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis","volume":"68","author":"Weintraub","year":"2011","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.cger.2019.09.004_bib39","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.cger.2019.09.004_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mdc3.12266","article-title":"Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action","volume":"3","author":"Yaw","year":"2015","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.cger.2019.09.004_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3\u00a0months\u2019 duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A\u00a0randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.cger.2019.09.004_bib44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomized, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2019.09.004_bib45","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2018.06.001","article-title":"Perspective on pimavanserin and the SASP-PD: novel scale development as a means to FDA approval","volume":"26","author":"Schubmehl","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.cger.2019.09.004_bib46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","article-title":"Screening for impulse control disorder symptoms in patients with de novo Parkinson disease: a case-control study","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib51","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.cger.2019.09.004_bib52","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/mds.27181","article-title":"Impulse control disorders in advanced Parkinson\u2019s disease with dyskinesia: the ALTHEA study","volume":"32","author":"Biundo","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","article-title":"Patient versus informant reporting ICD symptoms in Parkinson\u2019s disease using the QUIP: validity and variability","volume":"17","author":"Papay","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib54","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"A\u00a0European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson\u2019s disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib56","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.cger.2019.09.004_bib57","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib58","first-page":"143","article-title":"Impulse control disorders in Parkinson\u2019s disease: a cohort of 35 patients","volume":"168","author":"Carriere","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.cger.2019.09.004_bib59","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case-control study","volume":"69","author":"Voon","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cger.2019.09.004_bib60","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/mds.21296","article-title":"Punding prevalence in Parkinson\u2019s disease","volume":"22","author":"Miyasaki","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson\u2019s disease: from clinical and neuropsychological characterization to management and long-term outcome","volume":"85","author":"Cilia","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cger.2019.09.004_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson\u2019s disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.cger.2019.09.004_bib65","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann Neurol"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069019300795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069019300795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:54:14Z","timestamp":1760061254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069019300795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0749069019300795"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2019.09.004","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}